SAN JOSE, Calif., Sept. 8, 2020 /PRNewswire/ -- Anixa Biosciences,
Inc. (NASDAQ: ANIX), a biotechnology company focused on the
treatment and prevention of cancer and infectious diseases,
announced today that Dr. Amit Kumar,
Anixa's Chief Executive Officer, will present at the virtual 2020
H.C. Wainwright Global Investment Conference being held
September 14-16, 2020.
During the presentation, Dr. Kumar will provide an overview of
Anixa's business and highlight recent corporate achievements,
including its discovery of therapeutic candidates against Covid-19,
as well as anticipated milestones in its breast cancer vaccine and
CAR-T based ovarian cancer therapeutic programs.
Details of Anixa's presentation are as follows:
Wainwright 22nd Annual Global Investment
About Anixa Biosciences, Inc.
Anixa is a
publicly-traded biotechnology company developing a number of
programs addressing cancer and infectious disease. Anixa's
therapeutic portfolio includes a cancer immunotherapy program which
uses a novel type of CAR-T, known as chimeric endocrine receptor
T-cell (CER-T) technology, and a Covid-19 therapeutics program
focused on inhibiting certain viral protein function. Anixa's
vaccine portfolio consists of a technology focused on the
immunization against a "retired" protein, α-Lactalbumin, to prevent
triple negative breast cancer (TNBC), the most lethal form of
breast cancer. Anixa continually examines emerging
technologies in complementary fields for further development and
commercialization. Additional information is available at
Forward-Looking Statements: Statements that
are not historical fact may be considered forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are not
statements of historical facts, but rather reflect Anixa's current
expectations concerning future events and results. We
generally use the words "believes," "expects," "intends," "plans,"
"anticipates," "likely," "will" and similar expressions to identify
forward-looking statements. Such forward-looking statements,
including those concerning our expectations, involve risks,
uncertainties and other factors, some of which are beyond our
control, which may cause our actual results, performance or
achievements, or industry results, to be materially different from
any future results, performance, or achievements expressed or
implied by such forward-looking statements. These risks,
uncertainties and factors include, but are not limited to, those
factors set forth in "Item 1A - Risk Factors" and other sections of
our most recent Annual Report on Form 10-K as well as in our
Quarterly Reports on Form 10-Q and Current Reports on Form
8-K. We undertake no obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
law. You are cautioned not to unduly rely on such
forward-looking statements when evaluating the information
presented in this press release.
Tiberend Strategic Advisors, Inc.
Miriam Miller (Investors)
Johanna Bennett (Media)
View original content to download
SOURCE Anixa Biosciences, Inc.